New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India

Médecins Sans Frontières (MSF) clinic in Mumbai, India. To determine the final treatment outcomes, culture conversion and adverse events (AEs) during treatment among children and adolescents (0-19 years) with rifampicin-resistant tuberculosis (RR-TB) who received ambulatory injectable-free treatment...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of tuberculosis and lung disease Vol. 24; no. 12; p. 1265
Main Authors: Das, M, Mamnoon, F, Mansoor, H, Meneguim, A C, Singh, P, Shah, I, Ravi, S, Kalon, S, Hossain, F N, Ferlazzo, G, Isaakidis, P, Furin, J, Acharya, S, Thakur, H P
Format: Journal Article
Language:English
Published: France 01.12.2020
Subjects:
Adolescent
Antitubercular Agents - adverse effects
Child
Female
Humans
India
Male
Pharmaceutical Preparations
Retrospective Studies
Rifampin - adverse effects
Tuberculosis, Multidrug-Resistant - drug therapy
India
ISSN:1815-7920, 1815-7920
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Médecins Sans Frontières (MSF) clinic in Mumbai, India. To determine the final treatment outcomes, culture conversion and adverse events (AEs) during treatment among children and adolescents (0-19 years) with rifampicin-resistant tuberculosis (RR-TB) who received ambulatory injectable-free treatment, including bedaquiline (BDQ) and/or delamanid (DLM) during September 2014-January 2020. This was a retrospective cohort study based on review of routinely collected programme data. Twenty-four patients were included; the median age was 15.5 years (min-max 3-19) and 15 (63%) were females. None were HIV-coinfected. All had fluoroquinolone resistance. Twelve received treatment, including BDQ and DLM, 11 received DLM and one BDQ. The median exposure to BDQ ( = 13) and DLM ( = 23) was 82 (IQR 80-93) and 82 (IQR 77-96) weeks, respectively. Seventeen (94%) patients with positive culture at baseline ( = 18) had negative culture during treatment; median time for culture-conversion was 7 weeks (IQR 5-11). Twenty-three (96%) had successful treatment outcomes: cured ( = 16) or completed treatment ( = 7); one died. Eleven (46%) had 17 episodes of AEs. Two of 12 serious AEs were associated with new drugs (QTcF >500 ms). Based on one of the largest global cohorts of children and adolescents to receive new TB drugs, this study has shown that injectable-free regimens containing BDQ and/or DLM on ambulatory basis were effective and well-tolerated among children and adolescents and should be made routinely accessible to these vulnerable groups.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1815-7920
1815-7920
DOI:10.5588/ijtld.20.0165